Tycel Phillips, MD, discusses sonrotoclax’s FDA approval for mantle cell lymphoma and why the BCL2 inhibitor opens more possibilities.
|Videos|December 21, 2017
Dr. Wang Discusses Acalabrutinib in MCL
Author(s)Luhua (Michael) Wang, MD
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma.
Advertisement
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma (MCL).
Acalabrutinib is a second-generation BTK inhibitor that was recently approved by the FDA for the treatment of adult patients with MCL following at least 1 prior therapy.
Wang says that targeted therapies should not be underestimated in this disease, as they are a very powerful alternative to chemotherapy.
Advertisement
Related to this article
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
5